ChristopherLMoertelMD

Pediatric Hematology & Oncology • Minneapolis, MN

Pediatric Neuro-Oncology

Professor, Pediatrics, University of Minnesota Medical School

Join to view full profile

Dr. Moertel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Moertel's full profile

Already have an account?

Office
2450 Riverside Ave.
East Building, Ninth Floor
Minneapolis, MN 55454
Phone+1 612-365-8100

Fax+1 612-626-2815

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Pediatric Hematology/Oncology, 1987 - 1990
Baylor College of Medicine (Houston)Residency, Pediatrics, 1984 - 1986
University of Minnesota Medical SchoolClass of 1984

Certifications & Licensure

MN State Medical License 1987 - 2025
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
Recruiting
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Completed
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Start of enrollment: 2004 Feb 16
Completed
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
Active, not recruiting
Phase 3
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor Start of enrollment: 2010 Sep 01
Completed
Phase 1
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma Start of enrollment: 2012 Jul 17
Terminated
Phase 1
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas Start of enrollment: 2022 Jun 20
Recruiting
Phase 2, Phase 3
Roles: Contact
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Start of enrollment: 2015 Sep 01
Active, not recruiting
Phase 4
Roles: Contact
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas Start of enrollment: 2024 Dec 15
Not yet recruiting
Phase 2
Roles: Contact
A Phase II Trial of Poly-ICLC for Low-Grade Gliomas Start of enrollment: 2021 Dec 15
Recruiting
Phase 2
Roles: Contact
NF-1, Nutraceutical Intervention Start of enrollment: 2022 Jul 06
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

309 citations
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.
Eric Legius, Ludwine Messiaen, Pierre Wolkenstein, P Pancza, Robert A. Avery
Genetics in Medicine. 2021-05-19
31 citations
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas.
Hirokazu Ogino, Jennie W Taylor, Takahide Nejo, David Gibson, Payal B Watchmaker
The Journal of Clinical Investigation. 2022-02-01
52 citations
Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1.
Sara H. Isakson, Anthony E. Rizzardi, Alexander W. Coutts, Daniel F. Carlson, Mark N. Kirstein
Communications Biology. 2018-10-02

Press Mentions

MEK Inhibitor Scores Big Win in Adults, Children with Neurofibromatosis Type 1November 15th, 2024
No Link Between Mother's Pill Use and CNS Tumors in OffspringJanuary 4th, 2022
Unique Glioblastoma Treatment Sees Encouraging Early Results During Phase 1 Clinical TrialsNovember 17th, 2021
Join now to see all